BR0308923A - OligÈmeros de nucleobase de iap anti-sentido e empregos destes - Google Patents
OligÈmeros de nucleobase de iap anti-sentido e empregos destesInfo
- Publication number
- BR0308923A BR0308923A BR0308923-1A BR0308923A BR0308923A BR 0308923 A BR0308923 A BR 0308923A BR 0308923 A BR0308923 A BR 0308923A BR 0308923 A BR0308923 A BR 0308923A
- Authority
- BR
- Brazil
- Prior art keywords
- nucleobase oligomers
- antisense iap
- iap nucleobase
- antisense
- oligomers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Saccharide Compounds (AREA)
Abstract
"OLIGÈMEROS DE NUCLEOBASE DE IAP ANTI-SENTIDO E EMPREGOS DESTES". A presente invenção descreve oligómeros de nucleobase que hibridizam a polinucleotídeos de IAP, e métodos para empregá-los para realçar apoptose e tratar doenças proliferativas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36785302P | 2002-03-27 | 2002-03-27 | |
PCT/IB2003/001670 WO2003080638A2 (en) | 2002-03-27 | 2003-03-27 | Antisense iap nucleobase oligomers and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0308923A true BR0308923A (pt) | 2005-01-04 |
Family
ID=28454856
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0308923-1A BR0308923A (pt) | 2002-03-27 | 2003-03-27 | OligÈmeros de nucleobase de iap anti-sentido e empregos destes |
Country Status (17)
Country | Link |
---|---|
US (5) | US7091333B2 (pt) |
EP (1) | EP1490490B1 (pt) |
JP (2) | JP4486365B2 (pt) |
CN (1) | CN1656222B (pt) |
AT (1) | ATE431410T1 (pt) |
AU (1) | AU2003219432B2 (pt) |
BR (1) | BR0308923A (pt) |
CA (1) | CA2480308C (pt) |
DE (1) | DE60327618D1 (pt) |
DK (1) | DK1490490T3 (pt) |
ES (1) | ES2325660T3 (pt) |
IL (2) | IL164228A0 (pt) |
MX (1) | MXPA04009361A (pt) |
NZ (3) | NZ546806A (pt) |
PT (1) | PT1490490E (pt) |
WO (1) | WO2003080638A2 (pt) |
ZA (1) | ZA200407649B (pt) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6156535A (en) | 1995-08-04 | 2000-12-05 | University Of Ottawa | Mammalian IAP gene family, primers, probes, and detection methods |
US6133437A (en) * | 1997-02-13 | 2000-10-17 | Apoptogen, Inc. | Modulation of IAPs for the treatment of proliferative diseases |
EP1386004A4 (en) | 2001-04-05 | 2005-02-16 | Ribozyme Pharm Inc | MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
GB2406568B (en) * | 2002-02-20 | 2005-09-28 | Sirna Therapeutics Inc | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
ES2325660T3 (es) | 2002-03-27 | 2009-09-11 | Aegera Therapeutics Inc. | Oligomeros nucleobasicos de iap no codificantes y usos de los mismos. |
EP1927665A3 (en) * | 2002-11-19 | 2008-10-29 | CLLUone Therapeutics A/S | Methods and kits for diagnosing and treating b-Cell chronic lymphocytic leukemia (B-CLL) |
CA2524495A1 (en) * | 2003-06-03 | 2005-01-13 | Eli Lilly And Company | Modulation of survivin expression |
US8575327B2 (en) | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
US20050148535A1 (en) * | 2003-10-30 | 2005-07-07 | Lacasse Eric | IAP nucleobase oligomers and oligomeric complexes and uses thereof |
US8012944B2 (en) * | 2003-10-30 | 2011-09-06 | Pharmascience Inc. | Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent |
JP2007520522A (ja) * | 2004-02-05 | 2007-07-26 | ノバルティス アクチエンゲゼルシャフト | (a)DNAトポイソメラーゼ阻害剤および(b)IAP阻害剤の組み合わせ剤 |
JP2007523649A (ja) | 2004-02-10 | 2007-08-23 | サーナ・セラピューティクス・インコーポレイテッド | 多機能短鎖干渉核酸(多機能siNA)を用い、RNA干渉を介した遺伝子発現の阻害 |
EP1586654A1 (en) | 2004-04-15 | 2005-10-19 | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg | Replication competent viruses capable of silencing virus inhibitory factor expression |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
EP2397563A3 (en) * | 2004-09-17 | 2012-07-18 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
US20080293653A1 (en) * | 2004-10-14 | 2008-11-27 | Jon Durkin | Method of treating autoimmune diseases |
TWI401316B (zh) * | 2004-12-23 | 2013-07-11 | Alcon Inc | 用於治療青光眼之血清澱粉樣蛋白A的RNAi抑制作用 |
AU2006292293B2 (en) * | 2005-09-19 | 2012-09-13 | Isis Pharmaceuticals, Inc. | Modulation of glucocorticoid receptor expression |
JP4557051B2 (ja) * | 2008-06-17 | 2010-10-06 | セイコーエプソン株式会社 | プロジェクタ |
EP2609198B8 (en) | 2010-08-24 | 2018-03-28 | Sirna Therapeutics, Inc. | SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER |
WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
AU2012328680A1 (en) | 2011-10-25 | 2014-05-01 | Ionis Pharmaceuticals, Inc. | Antisense modulation of GCCR expression |
JOP20200092A1 (ar) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
JP7299839B2 (ja) * | 2017-03-24 | 2023-06-28 | ジェン-プローブ・インコーポレーテッド | パラインフルエンザウイルスを検出または定量化するための組成物および方法 |
LU100182B1 (en) * | 2017-04-06 | 2018-10-15 | Univ Hamburg Eppendorf Uke | Therapeutic use of microRNA 19A/19B |
US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
TW202023574A (zh) | 2018-08-13 | 2020-07-01 | 美商阿尼拉製藥公司 | B型肝炎病毒(HBV)dsRNA劑組合物及其使用方法 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5665550A (en) * | 1990-10-19 | 1997-09-09 | Board Of Trustees Of The University Of Illinois-Urbana | Genes and genetic elements associated with sensitivity to chemotherapeutic drugs |
WO1994008003A1 (en) * | 1991-06-14 | 1994-04-14 | Isis Pharmaceuticals, Inc. | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE |
US5594076A (en) | 1991-09-24 | 1997-01-14 | The Pennsylvania Research Foundation | Hydrodegradable polyesters |
US6265157B1 (en) * | 1991-12-03 | 2001-07-24 | Allegheny University Of The Health Sciences | Compositions and methods for detecting altered COL1A1 gene sequences |
US20030073159A1 (en) | 1992-05-11 | 2003-04-17 | Human Genome Sciences, Inc. | Human inhibitor of apoptosis gene 1 |
WO1994006814A1 (en) | 1992-09-14 | 1994-03-31 | The General Hospital Corporation | Ikaros: a t cell pathway regulatory gene |
US5958771A (en) * | 1998-12-03 | 1999-09-28 | Isis Pharmaceuticals, Inc. | Antisense modulation of cellular inhibitor of Apoptosis-2 expression |
US6087173A (en) * | 1999-09-09 | 2000-07-11 | Isis Pharmaceuticals Inc. | Antisense modulation of X-linked inhibitor of apoptosis expression |
US5958772A (en) | 1998-12-03 | 1999-09-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of cellular inhibitor of apoptosis-1 expression |
US5718883A (en) | 1993-04-14 | 1998-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Transgenic animal model for autoimmune diseases |
US5691179A (en) | 1993-08-26 | 1997-11-25 | Washington University | Cell death regulators |
US5624803A (en) * | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
US5510239A (en) * | 1993-10-18 | 1996-04-23 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of multidrug resistance-associated protein |
US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
CA2181548C (en) | 1994-01-18 | 2009-11-03 | Carlos F. Barbas, Iii | Zinc finger protein derivatives and methods therefor |
WO1995028497A1 (en) | 1994-04-13 | 1995-10-26 | La Jolla Cancer Research Foundation | Interaction of proteins involved in a cell death pathway |
SI9520059A (en) | 1994-05-10 | 1997-08-31 | Immulogic Pharma Corp | Compositions and treatment for multiple sclerosis. |
JP3944654B2 (ja) | 1994-10-18 | 2007-07-11 | ザ ユニバーシティー オブ オタワ | 神経細胞アポトーシスの抑制タンパクとその遺伝子配列、並びに脊髄性筋萎縮症の原因となる当該遺伝子の突然変異 |
WO1996012737A2 (en) | 1994-10-25 | 1996-05-02 | Immulogic Pharmaceutical Corporation | Compositions and treatment for multiple sclerosis |
WO1996020950A2 (en) | 1995-01-06 | 1996-07-11 | Immulogic Pharmaceutical Corporation | Compositions and methods for treating rheumatoid arthritis |
AU2548095A (en) | 1995-05-11 | 1996-11-29 | Human Genome Sciences, Inc. | Human inhibitor of apoptosis gene 1 |
US5770690A (en) | 1995-06-27 | 1998-06-23 | Neurex Corporation | Bax omega protein and methods |
US5877021A (en) * | 1995-07-07 | 1999-03-02 | Ribozyme Pharmaceuticals, Inc. | B7-1 targeted ribozymes |
US5919912A (en) * | 1995-08-04 | 1999-07-06 | University Of Ottawa | Mammalian IAP antibodies and diagnostic kits |
US6156535A (en) | 1995-08-04 | 2000-12-05 | University Of Ottawa | Mammalian IAP gene family, primers, probes, and detection methods |
US6187557B1 (en) * | 1995-08-08 | 2001-02-13 | Tularik Inc. | c-IAP1 and c-IAP2: inhibitors of apoptosis |
AU6692996A (en) | 1995-08-08 | 1997-03-05 | Tularik Inc. | Inhibitors of apoptosis |
US5834216A (en) | 1995-09-06 | 1998-11-10 | Arch Development Corporation | Screening methods for the identification of inducers and inhibitors of programmed cell death (apoptosis) |
AUPN727595A0 (en) | 1995-12-22 | 1996-01-18 | Walter And Eliza Hall Institute Of Medical Research, The | Therapeutic compositions |
US5605022A (en) * | 1995-12-26 | 1997-02-25 | Nci Building Systems, Inc. | Vented closure |
GB9601108D0 (en) | 1996-01-19 | 1996-03-20 | Univ Ottawa | Neuronal apoptosis inhibitor protein (NAIP) |
US6133437A (en) | 1997-02-13 | 2000-10-17 | Apoptogen, Inc. | Modulation of IAPs for the treatment of proliferative diseases |
AU5065098A (en) | 1996-11-15 | 1998-06-10 | University Of Ottawa | Modulators of ovarial apoptosis related to iap |
US5994076A (en) | 1997-05-21 | 1999-11-30 | Clontech Laboratories, Inc. | Methods of assaying differential expression |
US6228603B1 (en) | 1997-05-22 | 2001-05-08 | The Burnham Institute | Screening assays for agents that alter inhibitor of apoptosis (IAP) protein regulation of caspase activity |
CA2225187A1 (en) | 1997-07-14 | 1999-01-14 | Universite D'ottawa/ University Of Ottawa | Xaf genes and polypeptides: methods and reagents for modulating apoptosis |
US6133246A (en) | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
AU1080899A (en) | 1997-10-14 | 1999-05-03 | Nadine A. Tatton | Methods for increasing schwann cell survival |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
CN1312856A (zh) * | 1998-04-27 | 2001-09-12 | 利博齐姆医药公司 | 与丙型肝炎病毒感染相关的疾病或状态的酶性核酸治疗 |
US6171821B1 (en) * | 1998-07-24 | 2001-01-09 | Apoptogen, Inc. | XIAP IRES and uses thereof |
US6077709A (en) | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
US6492427B2 (en) | 1998-10-09 | 2002-12-10 | L. Sai Latha Shankar | Methods for treating multiple sclerosis |
US5998148A (en) * | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
KR20000065690A (ko) | 1999-04-08 | 2000-11-15 | 박종구 | 반응 특이성 및 안정성을 개선시킨 안티센스 올리고 뉴클레오타이드, 안티센스 dna 및 그 제조방법 |
US6395771B1 (en) | 2000-05-31 | 2002-05-28 | Dabur Research Foundation | Paclitaxel derivatives for the treatment of cancer |
US6673917B1 (en) * | 2000-09-28 | 2004-01-06 | University Of Ottawa | Antisense IAP nucleic acids and uses thereof |
US20020119168A1 (en) | 2001-02-20 | 2002-08-29 | Rudnic Edward M. | Therapeutic agent delivery |
KR100397275B1 (ko) * | 2001-03-08 | 2003-09-17 | 주식회사 웰진 | 단방향성 안티센스 cDNA 라이브러리 구축을 통한 신규대규모 유전자 검색 및 기능 분석 시스템 |
EP1572923A4 (en) | 2002-03-06 | 2007-10-31 | Rigel Pharmaceuticals Inc | NEW METHOD FOR THE INTRODUCTION AND INTRA-CELLULAR SYNTHESIS OF SIRNA MOLECULES |
ES2325660T3 (es) | 2002-03-27 | 2009-09-11 | Aegera Therapeutics Inc. | Oligomeros nucleobasicos de iap no codificantes y usos de los mismos. |
EP1469070A1 (en) | 2003-04-15 | 2004-10-20 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Livin-specific siRNAs for the treatment of therapy-resistant tumors |
CA2539752A1 (en) | 2003-09-29 | 2005-04-07 | Topigen Pharmaceutique Inc. | Oligonucleotide compositions and methods for treating disease including inflammatory conditions |
US8012944B2 (en) | 2003-10-30 | 2011-09-06 | Pharmascience Inc. | Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent |
-
2003
- 2003-03-27 ES ES03715244T patent/ES2325660T3/es not_active Expired - Lifetime
- 2003-03-27 CA CA2480308A patent/CA2480308C/en not_active Expired - Fee Related
- 2003-03-27 NZ NZ546806A patent/NZ546806A/en not_active IP Right Cessation
- 2003-03-27 CN CN038124246A patent/CN1656222B/zh not_active Expired - Fee Related
- 2003-03-27 NZ NZ535461A patent/NZ535461A/en not_active IP Right Cessation
- 2003-03-27 DK DK03715244T patent/DK1490490T3/da active
- 2003-03-27 MX MXPA04009361A patent/MXPA04009361A/es unknown
- 2003-03-27 BR BR0308923-1A patent/BR0308923A/pt not_active IP Right Cessation
- 2003-03-27 AU AU2003219432A patent/AU2003219432B2/en not_active Ceased
- 2003-03-27 PT PT03715244T patent/PT1490490E/pt unknown
- 2003-03-27 US US10/400,382 patent/US7091333B2/en not_active Expired - Fee Related
- 2003-03-27 EP EP03715244A patent/EP1490490B1/en not_active Expired - Lifetime
- 2003-03-27 DE DE60327618T patent/DE60327618D1/de not_active Expired - Lifetime
- 2003-03-27 NZ NZ546807A patent/NZ546807A/en not_active IP Right Cessation
- 2003-03-27 IL IL16422803A patent/IL164228A0/xx unknown
- 2003-03-27 WO PCT/IB2003/001670 patent/WO2003080638A2/en active Application Filing
- 2003-03-27 AT AT03715244T patent/ATE431410T1/de active
- 2003-03-27 JP JP2003578391A patent/JP4486365B2/ja not_active Expired - Fee Related
-
2004
- 2004-09-22 IL IL164228A patent/IL164228A/en not_active IP Right Cessation
- 2004-09-22 ZA ZA200407649A patent/ZA200407649B/en unknown
-
2006
- 2006-05-30 US US11/442,380 patent/US20070032445A1/en not_active Abandoned
- 2006-06-08 US US11/448,862 patent/US7638620B2/en not_active Expired - Fee Related
- 2006-06-30 US US11/477,452 patent/US7638497B2/en not_active Expired - Fee Related
- 2006-10-26 US US11/586,554 patent/US20070135371A1/en not_active Abandoned
-
2009
- 2009-09-17 JP JP2009215798A patent/JP2010042009A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0308923A (pt) | OligÈmeros de nucleobase de iap anti-sentido e empregos destes | |
NO20091661L (no) | Anvendelse av pegylert IL-10 for a behandle kreft | |
TW200736231A (en) | Substituted pyrimidines | |
AP2212A (en) | Phosphonates, Monophosphonamidates, Bisphosphonamidates for the treatment of viral diseases. | |
MX2009006536A (es) | Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales. | |
EA201190178A1 (ru) | Замещённые нуклеозидные и нуклеотидные аналоги | |
JO3235B1 (ar) | مركبات بيررولوبيريميدين و استعمالاتها | |
WO2004041203A3 (en) | Gemcitabine prodrugs, pharmaceutical compositions and uses thereof | |
TNSN08400A1 (en) | Organic compounds and their uses | |
TW200510343A (en) | Substituted dihydroquinazolines | |
EA200601074A1 (ru) | Применение производных пептидов для лечения болей, связанных с заболеванием центральной нервной системы (центральной невропатической боли) | |
EP1667685A4 (en) | INHIBITORS OF QUINAZOLINE-BASED POTASSIUM CANAL | |
WO2003105755A3 (en) | ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR C (VEGF-C) EXPRESSION | |
PL1843771T3 (pl) | Zastosowanie pirymidyloaminobenzamidów do leczenia chorób odpowiadających na modulację aktywności kinazy Tie-2 | |
DK1893213T3 (da) | Kombination af pyrimidylaminobenzamidforbindelser og imatinib til behandling eller forebyggelse af proliferative sygdomme | |
DK1223930T3 (da) | Behandling af dyskinesi | |
DE602004019541D1 (de) | Cycloalkyläbü kondensierte indole | |
AU2003234342A8 (en) | Ablated slam-dependent entry | |
NO20072048L (no) | Anvendelse av IL-17F for behandling og/eller forebygging av neurologiske sykdommer. | |
MY166063A (en) | Intravenous antiviral treatments | |
UA85187C2 (en) | 2-aminobenzoyl derivatives | |
PL1612210T3 (pl) | Nowe analogi nitrobenzylotioinozyny | |
WO2003105754A3 (en) | ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR B (VEGF-B) EXPRESSION | |
WO2003106645A3 (en) | ANTISENSE MODULATION OF SMRT COREPRESSOR EXPRESSION | |
DE60326348D1 (de) | Makrozyclen zur behandlung von krebserkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: PHARMASCIENCE INC. (CA) Free format text: TRANSFERIDO DE: AEGERA THERAPEUTICS, INC. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014. |